RS60701B1 - Primena reslizumaba za tretman umerene do ozbiljne eozinofilne astme - Google Patents

Primena reslizumaba za tretman umerene do ozbiljne eozinofilne astme

Info

Publication number
RS60701B1
RS60701B1 RS20200977A RSP20200977A RS60701B1 RS 60701 B1 RS60701 B1 RS 60701B1 RS 20200977 A RS20200977 A RS 20200977A RS P20200977 A RSP20200977 A RS P20200977A RS 60701 B1 RS60701 B1 RS 60701B1
Authority
RS
Serbia
Prior art keywords
reslizumab
eosinophilic asthma
treat moderate
severe eosinophilic
severe
Prior art date
Application number
RS20200977A
Other languages
English (en)
Inventor
Guy Brusselle
Christopher O'brien
James Zangrilli
Tushar Shah
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of RS60701B1 publication Critical patent/RS60701B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
RS20200977A 2014-09-08 2015-08-28 Primena reslizumaba za tretman umerene do ozbiljne eozinofilne astme RS60701B1 (sr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462047248P 2014-09-08 2014-09-08
US201462091150P 2014-12-12 2014-12-12
US201562168007P 2015-05-29 2015-05-29
US201562191690P 2015-07-13 2015-07-13
EP15760590.8A EP3191513B1 (en) 2014-09-08 2015-08-28 Use of reslizumab to treat moderate to severe eosinophilic asthma
PCT/US2015/047357 WO2016040007A1 (en) 2014-09-08 2015-08-28 Use of reslizumab to treat moderate to severe eosinophilic asthma

Publications (1)

Publication Number Publication Date
RS60701B1 true RS60701B1 (sr) 2020-09-30

Family

ID=54066234

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20200977A RS60701B1 (sr) 2014-09-08 2015-08-28 Primena reslizumaba za tretman umerene do ozbiljne eozinofilne astme

Country Status (19)

Country Link
US (2) US9815894B2 (sr)
EP (1) EP3191513B1 (sr)
KR (1) KR102495432B1 (sr)
CN (1) CN107073114B (sr)
AU (1) AU2015315628A1 (sr)
CA (1) CA2962944A1 (sr)
CY (1) CY1123501T1 (sr)
DK (1) DK3191513T3 (sr)
EA (1) EA034864B1 (sr)
ES (1) ES2811124T3 (sr)
HR (1) HRP20201307T1 (sr)
HU (1) HUE050202T2 (sr)
PL (1) PL3191513T3 (sr)
PT (1) PT3191513T (sr)
RS (1) RS60701B1 (sr)
SI (1) SI3191513T1 (sr)
UA (1) UA122670C2 (sr)
WO (1) WO2016040007A1 (sr)
ZA (1) ZA201702247B (sr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180056018A1 (en) * 2016-08-31 2018-03-01 Cephalon, Inc. Inhalation Systems, Devices and Methods
EP3634434A4 (en) * 2017-05-12 2021-06-09 The Regents of The University of California TREATMENT AND DETECTION OF DYSBIOSIS
MX2020003034A (es) 2017-09-29 2020-07-22 Jiangsu Hengrui Medicine Co Anticuerpo il-5, fragmento de union a antigeno del mismo y su aplicacion medica.
AU2020251627A1 (en) 2019-03-29 2021-11-11 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing antibody against IL-5 and use thereof
CN113966229A (zh) 2019-05-10 2022-01-21 爱沐疗法公司 用于改善花生过敏患者的生活质量的方法
TW202126688A (zh) * 2019-09-27 2021-07-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療遲發性氣喘之方法
EP3957308A1 (en) 2020-08-21 2022-02-23 Palobiofarma, S.L. (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ291039B6 (cs) 1992-02-06 2002-12-11 Schering Corporation Monoklonální protilátka, hybridom, polypeptid a způsob jeho přípravy, izolovaná DNA, rekombinantní vektor, hostitelská buňka, humanizovaná protilátka a farmaceutický prostředek
USRE39548E1 (en) 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
US6056957A (en) 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
JP5917143B2 (ja) * 2008-03-28 2016-05-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 処置方法
WO2011156000A2 (en) * 2010-06-07 2011-12-15 Aerovance, Inc. Use of il-4/il-13 antagonists to treat eosinophilic disorders
TW201732294A (zh) * 2010-12-16 2017-09-16 建南德克公司 關於ｔｈ２抑制作用之診斷及治療

Also Published As

Publication number Publication date
KR102495432B1 (ko) 2023-02-03
EA201790563A1 (ru) 2017-08-31
US9815894B2 (en) 2017-11-14
EA201790563A8 (ru) 2017-11-30
DK3191513T3 (da) 2020-08-24
EA034864B1 (ru) 2020-03-31
PT3191513T (pt) 2020-07-31
HUE050202T2 (hu) 2020-11-30
AU2015315628A1 (en) 2017-04-20
ES2811124T3 (es) 2021-03-10
CY1123501T1 (el) 2022-03-24
KR20170072197A (ko) 2017-06-26
CA2962944A1 (en) 2016-03-17
SI3191513T1 (sl) 2020-12-31
US20160102144A1 (en) 2016-04-14
CN107073114B (zh) 2022-01-14
WO2016040007A1 (en) 2016-03-17
ZA201702247B (en) 2018-08-29
PL3191513T3 (pl) 2021-02-08
NZ730541A (en) 2023-10-27
US10577414B2 (en) 2020-03-03
HRP20201307T1 (hr) 2020-11-27
EP3191513A1 (en) 2017-07-19
US20180030131A1 (en) 2018-02-01
EP3191513B1 (en) 2020-06-24
CN107073114A (zh) 2017-08-18
UA122670C2 (uk) 2020-12-28

Similar Documents

Publication Publication Date Title
IL286888A (en) Use of pyridofidine to treat depression and anxiety
IL251066A0 (en) Preparations and methods for the treatment of metabolic disorders
ZA201700311B (en) Compositions and methods of use for treating metabolic disorders
GB201701673D0 (en) Methods of well treatment
HK1243325A1 (zh) 用於治療視覺障礙的組合物和方法
ZA201702247B (en) Use of reslizumab to treat moderate to severe eosinophilic asthma
IL280039A (en) Preparations and methods related to the diagnosis of prostate cancer
GB201410250D0 (en) Improvements to nasal compositions and method of use thereof
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
HK1259445A1 (zh) 治療癌症的組合
HK1244711A1 (zh) Hmgb1介導的炎症的治療
GB2545126B (en) Use of carbonates as wellbore treatment
ZA201606450B (en) Compounds and their methods of use
LT2964027T (lt) Derinių, apimančių klokvintocet-meksilą, panaudojimas augalų derliaus pagerinimui
IL251736B (en) Methods and compositions for the treatment of radiation-related disorders
PT3393517T (pt) Ácido acetilsalicílico para utilização no tratamento de influenza moderada a grave
IL259781A (en) Uses of pyrimido-pyridazinones to treat cancer
EP3157542A4 (en) Methods to treat inflammation of the lung
ZA201504639B (en) Treatment of water
ZA201408464B (en) Composition for the use in treatment of asthma
TWM489082U (en) Structure of woods
TWM490331U (en) Improved structure of mask